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 INTRODUCTION 
 
 Carcinoma breast is one of the most common cancers afflicting 
the females. The presentation of carcinoma breast gives as varied a 
panorama as the surgical field itself. Locally advanced carcinoma breast 
is one of the most common modes of presentation of carcinoma breast in 
the surgical wards. The lack of awareness in the general populace 
regarding breast lumps in general and the explicit mode of presentation 
of LABC contribute to the plethora of forms of appearance of this 
disease. 
The various modalities of therapy offered to patients with LABC 
and the synchronized mode of treatment protocol are needed to 
ensure adequate control of morbidity and mortality of this disease. 
The fine line between wide-spread metastasis signifying a death 
sentence and an eminently controllable situation epitomized by LABC is 
of primal importance in the study and therapy of breast cancer. The 
slowly increasing incidence of LABC in the general female populace also 
stresses the need to gain more insight into the behavioral pattern of 
this dreaded disease. The importance of adjuvant therapy in the form 
of chemo/radio/endocrine and the modality of administration of the 
 same and the type of surgical remedies offered are also in need of 
critical evaluation 
This study is an attempt to understand the profile of the disease 
as is epitomized in the presentation of the LABC in Tirunelveli Medical 
College Hospital and an effort has been made to analyze the disease in 
its entirety. It also entails a comparison to the picture of LABC in 
clinical situations in other institutions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 AIMS AND OBJECTIVES 
 The aims of this study are epitomized as follows: 
a) To study and understand the factors in the patho physiology 
of the LABC and evaluate the factors responsible. 
 
b) To analyze the variables involved in the causation and etio 
pathogenesis of locally advanced breast cancer. 
 
c) To understand the importance of the various risk factors 
involved in the interplay of manifestations of this disease 
 
d) To evaluate the efficacy of multimodality treatment as 
provided in this institution 
 
e) To compare the efficiency of treatment protocols by way of 
incidence of loco regional recurrences. 
  
 
                     
 MATERIALS AND METHODS 
This study is based on the follow up of patients with locally 
advanced breast cancer who were studied during the period between 
July 2004 and July 2006. 
 
 A total of one hundred and fourteen patients under went 
surgery for symptoms and diagnosis of carcinoma breast, of which 
thirty-nine patients who had locally advanced breast cancer were 
studied in detail as they presented for regular follow-up at Tirunelveli 
Medical College Hospital. 
 
The selection criteria of patients were based on the TNM 
classification of breast cancers from stage II B, stage III A and 
stage III B were selected. 
            
                     The modalities of diagnosis and treatment of breast 
cancer as is being done in Tirunelveli Medical College Hospital forms 
the crux of this study. 
 Meticulous history followed by thorough clinical examination and 
routine biochemical and radiological examinations, invasive procedures 
for diagnosis like FNAC formed the basis of stratification of patients. 
 
The investigative protocols of hormonal receptor assay and 
sentinel nodal biopsy were not applied due to their non-availability in 
this institution. 
 
Patients were followed up as they underwent various modalities 
of treatment in the form of surgery, neoadjuvant and adjuvant 
chemotherapy and radiotherapy supplemented by hormonal therapy. 
 
No attempt was made to modify the treatment protocols of the 
various units under whose care these patients were treated. An effort 
has been made to study the profile of locally advanced breast cancer 
as managed in Tirunelveli Medical College Hospital 
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LOCALLY ADVANCED CARCINOMA BREAST 
HISTORICAL ASPECTS 
    
The breast has always been a symbol of womanhood and fertility. 
Cosmetic considerations and fear of infertility have always hindered 
early diagnosis and prompt treatment of disorders of the breast. 
Breast diseases have been in vogue since the times of Herodotus 
and Democedes(525 B.C.) The Edwin Smith surgical papyrus (3000-
2500B.C.) makes special mention of breast disorders. Aulus Celsus in 
the first century A.D. and Galen provide detailed accounts of 
treatment of carcinoma breast.  Leonides of Alexandria was the first 
to stress the importance of retraction of the nipple in breast cancer 
Caustics were the treatment modalities in the times of the 
Egyptians, Romans and Greeks. Paul of Aegina(625),Vasalius(1514) give 
detailed descriptions of amputation of breast. Ambroise  Pare(1510-
1590) the great French surgeon treated breast lumps with wide 
excision.  
With the description of François Le Dran regarding spread of 
tumor to lymphatics surgeons like Petit skillfully and successfully 
 attempted block dissection Sir James Paget’s treatise in 1836 
provided rare insights into the realm of breast diseases. Charles 
Moore in 1867 with the advantage of microscopic pathology underlined 
the importance of tumor free margins.  
Though Volkmann (1875), Gross (1880), Banks, Sprengel (1882) 
and Kuster (1883) gave broad outlines regarding radical mastectomy it 
remained for Halstead and Meyer to propound the nuances of radical 
mastectomy as a form of definitive cure for breast cancer in 1894 
Subsequently more conservative procedures were adopted by 
McWhirter(1948),Patey(1948) and Madden(1965)witnessing a paradigm 
shift in breast cancer treatment. 01 
With the acclamation of the Fisherian theory (1985) the focus 
has now shifted to less mutilating surgeries supplemented with multi 
modality therapy. 
 The advent of sentinel nodal biopsy for breast cancer in the 
mid-90’s has revolutionized treatment procedures. 
 Improvements in administration of radiotherapy, chemotherapy 
and endocrine therapy from Sir Astley Cooper’s time in 1836 to use of 
fulvestrant as a estrogen receptor down-regulator have made breast 
 cancer a less frightening disease for patients and a more manageable 
disease for surgeons. The advent of modern diagnostics and the role of 
reconstructive surgery have also played an important role in reduction 
of morbidity and mortality from breast cancer.                                                            
BREAST EMBRYOLOGY 
It is essential that the surgeon dealing with breast abnormalities 
must be familiar with their embryologic antecedents, for only through 
this knowledge can variations in glandular location, shape or number and 
rationale for surgical maneuvers be appreciated. The breast is 
considered as a modified sudoriferous gland which develops as 
ingrowths from the ectoderm supported by vascularized mesenchyme 
.In the fifth to sixth weeks mammary ridges develop extending from 
axilla to inguinal region, the human mammary glands develop from the 
pectoral aspect of these ridges. Supernumerary rudiments develop 
along the path of the mammary ridges.02 
              As each mammary primordium develops, its ectodermal 
ingrowths develop into 15-20 solid buds of ectoderm to form the 
eventual lactiferous ducts and their associated lobes of alveoli in the 
fully formed gland. These are surrounded by mesenchyme which forms 
 
 the connective tissue, fat, vasculature and is invaded by nerves. By 
proliferation, elongation and further branching, the alveoli are formed 
and the duct system defined. During the last two months of gestation 
the ducts become canalized and the epidermis at the point of original 
development of the gland forms a small mammary pit into which the 
lactiferous ducts open. Perinatally the nipple forms by mesenchymal 
proliferation. At birth the mammary glands are similar in both sexes 
but in females at puberty, pregnancy and lactation they undergo 
further hormone dependent developmental changes03 
DEVELOPMENTAL   ANATOMY 
The normal breast is composed of ducts and lobules lined by 
two cell types ,a low flattened discontinuous layer of contractile 
cells containing myofilament cells on the basement membrane 
assisting milk ejection and a second layer of epithelial cells lining 
the luminal surfaces. the luminal cells of the terminal duct and 
the lobule produce milk but those lining the large duct system do 
not. A committed stem cell in the terminal duct is postulated to 
give rise to both luminal and myoepithelial cells. 
 Six to ten major ducts originate at the nipple. Successive 
branching of large ducts leads to the terminal duct lobular unit 
(TDLU). In the adult female the terminal duct branches into 
grape-like cluster of small acini to form a lobule04 
The uniqueness of the breast lies in the cyclic changes that 
occur during the reproductive life  
The prepubertal breast in males and females has minimal 
lobule formation. at the beginning of menarche lobular formation 
and interlobular stromal development occurs, there is a paucity of 
adipose tissue and the breast appears radio-dense. There is a 
proliferative and apoptotic activity in consonance with the 
menstrual cycle. 
With pregnancy there is a reversal of the lobular stromal 
ratio due to proliferation of lobules. After cessation of lactation 
the lobules regress and atrophy, however there is a permanent 
increase in the size and number of lobules.05 
Involution starts after the third decade, the lobules almost 
totally disappear creating a morphologic pattern resembling the 
 male breast the increase in adipose tissue contributing to the 
radiolucent pattern in mammograms 
OVERVIEW OF ANATOMY 
The mature female breast extends from the level of second 
rib to the inframammary fold at the level of the sixth or seventh 
rib laterally extending from the sternum to the anterior or mid-
axillary line. The deep surface lies on the investing fasciae of the 
pectoralis major, serratus anterior and external oblique muscle 
and upper extent of the rectus sheath.the axillary tail of Spence 
extends into the anterior axillary fold.the upper outer quadrant 
contains more glandular tissue than the rest of the breast. 
The glandular portion of the breast forms a protuberant 
cone about 10 to12 cm in diameter and 5 to 7 cm in thickness. A 
typical non-lactating breast weighs between 150 and 225 grams.03 
The breast of the nulliparous female has a typical 
hemispheric configuration with a flattening above the nipple. With 
pregnancy and lactation the breast increases in size and becomes 
 more pendulous. As age increases the breast becomes flattened 
and less firm with a decrease in volume. 
The breast is located in the hypodermis, the layer deep to 
the dermis. In approaching the breast the dissection is done in 
this plane which is bloodless, raising a flap of thickness of about 2 
– 3 mm. The blood vessels and lymphatics passing in the deeper 
layer of the superficial fascia are left undisturbed.06 
Anterior fibrous processes, the suspensory ligaments of 
cooper pass from the septa that divide these lobules to insert 
into the skin. Posteriorly the separation from the pectoral fascia 
is by the retro mammary space or bursa. The two structures allow 
the breast to move freely against the thoracic wall. Connective 
tissue thickenings, the posterior suspensory ligaments attach the 
deep surface of the breast to the pectoralis fascia, hence the 
common practice to remove the adjacent portion of the pectoralis 
major with the breast tissue. As the breast extends into the 
axilla ,it has contact with the deep fascia of that region.  
 The working knowledge of the anatomy of the axilla is of 
paramount importance in breast surgery. The axilla is a pyramidal 
compartment having four walls, an apex and a base. The base is 
formed by the axillary fascia and skin, the apex leads to the 
cervico-axillary canal, the anterior wall is formed by the 
pectoralis major, posterior wall by the subscapularis, the lateral 
wall by the bicipital groove of the humerus and the medial wall by 
the serratus anterior and the thoracic wall. 
The contents of the axilla are the great vessels of the 
upper extremity closely associated with each other and enclosed 
within the axillary sheath. Apart from the axillary artery and its 
branches, the axillary vein and its tributaries, the brachial plexus 
is very vulnerable during axillary dissection especially the ansa 
pectoralis 07 (communicating branch between lateral and medial 
pectoral nerves),08the long thoracic nerve causing paralysis of the 
serratus anterior and the intercostobrachial, a nerve commonly 
injured in axillary dissection causing numbness over the medial 
aspect of the arm.               
 BLOOD SUPPLY 
   The breast receives its blood supply from the perforating 
branches of the internal mammary artery ;lateral branches of the 
posterior intercostals arteries; and several branches of the axillary  
artery including highest thoracic, lateral thoracic and pectoral 
branches of the thoracoacromial artery 
Branches  from the second, third ,and fourth anterior 
perforating arteries pass to the breast as medial mammary 
arteries,these vessels enlarge during lactationthe lateral thoracic 
artery gives rise to the lateral mammary branches; in the second ,third 
and fourth intercostals spaces the posterior intercostals arteries give 
off the mammary branches, all these vessels also enlarge during 
lactation. 
The thoracodorsal branch of the subscapular artery though not 
of importance in the supply to the breast is intimately associated with 
the central and scapular group of lymph nodes and may cause major 
bleeding that is difficult to control during lymph node dissection.09 
The venous tributaries follow the pattern of arterial supply and 
drain chiefly to the axilla the superficial veins around the nipple form 
 the circulus venosus from which blood passes through the substance of 
the breast and reaches the periphery into the principal group of veins. 
Metastatic emboli reach the lungs through this direct venous route.the 
posterior intercosyal vessels are in direct continuity with the posterior 
vertebral plexuses of veins and these open a second portal of channel 
for direct metastasis to the vertebral bodies, ribs , and central 
nervous system10. 
Sensory innervation of the breast is supplied primarily by the 
lateral and anterior cutaneous branches of the second through sixth 
intercostal nerves;a small segment superiorly is supplied by the 
supraclavicular nerves.the intercostobrachial,lateral and medial 
mammary nerves also complete the nervous innervation.11 
LYMPHATIC DRAINAGE OF BREAST 
The lymphatic drainage is of utmost importance in the study of 
carcinoma breast. Anatomically defined lymphatic groups are 
(1) Lateral /axillary vein group-four to six lymph 
nodes lying medial or posterior to the axillary vein 
draining the upper extremity except those that 
 drain into the deltopectoral lymph nodes the 
infraclavicular group 
(2) Anterior/Pectoral/External mammary group-four 
to five nodes that are situated along the lower 
border of pectoralis minor receiving the major 
lymphatic drainage from the breast. Lymph from 
these nodes flow to the central group of nodes ; 
some may pass to the subclavicular nodes 
(3) Subscapular/Posterior/Scapular group-six to seven 
nodes along the posterior border of the axilla  at 
the lateral border of scapula receiving flow from 
the posterior aspects of the neck, trunk and 
scapula passing to the central and subclavicular 
nodes 
(4) Central group- three to four large nodes embedded 
in the fat of the axilla posterior to the pectoralis 
minor muscle. Commonly palpable as they are 
superficially placed hence allowing estimation of 
 metastatic disease. Lymph from these nodes passes 
to the subclavicular nodes.  
(5) Subclavicular/Apical nodes- six to twelve nodes 
located partly posterior and partly superior to the 
pectoralis minor extending to the apex of the axilla 
along the medial side of the axillary vein receiving 
lymph from all other nodes either directly or 
indirectly. The efferents pass to the subclavian 
trunk hence passing to the thoracic duct on the left 
and right lymphatic trunk 
(6) Rotter’s/Interpectoral nodes- one to four lymph 
nodes located between the pectoralis major and 
minor passing to the central and subclavicular nodes  
               The surgical definition of the axillary lymph nodes is 
defined by their relationship to the pectoralis minor muscle. 
Lymph nodes located lateral or below the lower border of the 
muscle are labeled level I and include the external mammary, 
axillary vein, scapular lymph node groups. The central and 
some of the subclavicular nodes located deep or posterior to 
 the pectoralis minor are labeled level II. Those lymph nodes 
located medial or superior to the muscle are called level III 
and include the subclavicular lymph node group.12 
           Lymph nodes of the thoracic wall and those draining 
the thoracic cavity namely the parasternal, 
intercostals,diaphragmatic, anterior mediastinal, posterior 
mediastinal, and tracheobronchial also are eminently involved 
in the spread of cancer cells in cancer breast. 
                The internal mammary nodal group anatomically 
situated in the retrosternal interspaces between the costal 
cartilages near the sternal margin and the supraclavicular 
lymph nodes representing the termination of the major 
lymphatic trunks situated beneath the lateral margin of the 
inferior aspect of the sternocleidomastoid beneath the 
clavicle represent common sites of distant metastasis in 
mammary carcinoma.   
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   CLINICO-PATHOLOGIC  CONSIDERATIONS   
              Clinico-pathologic considerations play an important role in 
prediction of long term outcome in patients with breast cancer. 
Generally accepted prognostic factors include  
Clinical factors 
         Clinical staging is based on a thorough physical examination of 
the breast tissue, skin overlying the breasts, regional lymph nodes and 
various imaging modalities. Important characteristics in physical 
examination are tumor size, extension into chest wall, overlying skin 
(erythema, edema, ulceration) and the regional lymph nodes; mobility of 
which is an important prognostic indicator with fixed nodes having a 
worse prognosis. Imaging modalities such as mammograms, CT scans, 
serve as adjuncts to physical examination, newer imaging options 
include digital mammography, MRI scans and PET13. 
PRIMARY TUMOR CHARACTERISTICS 
(a) AGE 
           The influence of age and menopausal status at diagnosis 
on the prognosis of patients with primary breast cancer remains 
controversial. Some studies have found that younger patients have 
 worse clinical outcomes than older patients. Others have reported 
that younger patients have a more favorable outcome. Still others 
have found no relation between outcome and age. Explanations for 
these conflicting results have included small numbers of patients in 
the studies, differences in patient selection, and differences in the 
age groupings used in the analyses. 
(b) TUMOR SIZE 
 Defined as the maximal size of the invasive component of the 
primary tumor on pathologic specimen. Clinical examination of 
size has been included as an independent predictor for 
survival. Metastasis does not occur until a size of 3.6 cm 
diameter is reached. Axillary nodal metastasis occurs more 
consistently when tumor size is 3.1- 4.0 cm in diameter. 
Disease free survival and overall prognosis is also dependent 
on tumor size.14 
(c) TUMOR LOCATION 
            In patients with negative nodes location plays an important                         
role in defining prognosis. The risk of axillary metastasis increases in 
lateral versus medial cancers. Studies also indicate that medial and 
 central locations are associated with two-fold increase in developing 
systemic relapse and breast cancer related death due to risk of occult 
spread to the internal mammary nodes.15  
(d)     TUMOR HISTOLOGY                                                                                    
  
 The histologic classification of malignant breast tumors include 
EPITHELIAL TUMORS 
carcinoma, NOS (not otherwise specified) 
ductal  
intraductal (in situ)  
invasive with predominant intraductal component  
invasive, NOS  
comedo  
inflammatory  
medullary with lymphocytic infiltrate  
mucinous (colloid)  
papillary  
scirrhous  
 tubular  
other  
lobular  
in situ  
invasive with predominant in situ component  
invasive  
nipple  
Paget's disease, NOS  
Paget's disease with intraductal carcinoma  
Paget's disease with invasive ductal carcinoma  
other  
undifferentiated carcinoma                                                                      
 
 MIXED CONNECTIVE TISSUE AND EPITHELIAL TUMORS    
MISCELLANEOUS TUMORS 
UNCLASSIFIED TUMORS16 
Of the malignant tumors, the medullary, papillary, and colloid subtypes 
have a better prognosis than do ductal invasive tumors Hoge and 
colleagues classify tumors based on histologic characteristics as 
  ] 
       CLASS A       all in-situ lesions      91%    5-yr survival   
     CLASS B      medullary, mucinous, tubular,adenoid cystic  75% 5-yr   
survival             
   CLASS C        infiltrating ductal and lobular carcinomas   66% 
survival 
    CLASS D             inflammatory and undifferentiated carcinomas   
33% survival rate17         
(e)TUMOR GRADE       
   Histologic grading is based on Bloom and Richardson’s criteria 
such as size, shape and hyperchromatism along with percentage and 
number of mitotic figures and tubules. Survival was estimated to be 
41% for grade 1, 29% for grade 2 and 21% for grade 3. The SBR 
grading system consists of three components (degree of 
differentiation, extent of pleomorphism, and mitotic index), each 
scored on a scale from 1 to 3. The degree of differentiation is 
evaluated according to the ability of the tumor to form tubular, 
glandular, or papillary formations. Pleomorphism describes the shape of 
the nuclei, with particular attention to irregular cells distorted in size. 
The mitotic index evaluates the number of mitoses found in the tumor 
 specimen. The scores for the three components are summed and 
categorized as grade 1 (well differentiated), grade 2 (moderately 
differentiated), or grade 3 (poorly differentiated). A modified SBR 
(MSBR) system considers only the extent of pleomorphism and the 
mitotic index, and rearranges the scoring system to yield five 
classifications of nuclear grade.18 
Fisher's grading system includes a combined assessment of 
nuclear grade and the presence of tubule or gland formation. Nuclear 
grade considers nuclear size, shape, nucleolar content, chromatin 
pattern, and mitotic rate. Although histologic grading is only applicable 
to the invasive component of ductal carcinomas, the nuclear grade can 
be determined on all components of all histologic types of breast 
cancer.19 
(f) RECEPTOR STATUS 
             Receptor status forms an important aspect of 
determining the prognostic evaluation in breast cancer. ER and PR 
positivity correlates with better prognosis and response to 
chemotherapy with nor without use of tamoxifen. Another study 
 indicates longer survivorship for patients with PR positive tumors 
compared to PR negative cohorts20 
(g) LYMPH NODE STATUS 
        The presence of lymph nodes obviously indicates a worse 
prognosis but the location of positive nodes is also of primal 
importance. Involvement of apical axillary and infraclavicular nodes 
indicate grim prognosis. Internal mammary nodal involvement markedly 
decreases overall survival. Supraclavicular nodes are considered to 
indicate systemic spread but recent studies indicate survival rates 
that parallel those with locally advanced disease. Data indicate that 
metastasis to nodal groups other than regional suggest the presence of 
systemic disease.21 
(h)  LOCALLY ADVANCED /INFLAMMATORY CANCER 
BREAST 
              Tumors invading into skin or skeletal muscle are 
associated with concurrent or subsequent systemic disease. Women 
presenting with clinical appearance of breast swelling and skin 
induration (inflammatory breast cancer) have a particularly poor 
prognosis with 3 year survival rates of only 3% to10% 
 (i)  LYMPHOVASCULAR INVASION 
             Tumor cells may be seen within vascular spaces 
surrounding tumors. This finding is strongly predictive of lymph node 
metastasis and associated with a poor prognosis.Presence of tumor 
cells in dermal lymphatics is strongly associated with inflammatory 
breast cancer and a poor prognosis. 
(j) BIOLOGIC FACTORS 
Biologic prognostic factors include 
(1) Angiogenesis  -VEGF 
(2) Proliferation –(MIBI/Ki67/TLI) 
(3) Growth factor receptors- EGFR/cerbB2/cneu 
(4) Cellcycle regulators-p53/c-myc/cyclins 
(5) Proteases- urokinase/plasminogen activator/cathepsin D 
(6) Metastasis proteins –laminin 67kDa receptor/nm23 
(7) Heat shock proteins- 
(k) OTHER CHARACTERISTICS  
(1) Age at menarche- 
        Women reaching menarche before 11 years of age have a 
20% increased risk compared to those attaining menarche at 14. 
 (2) First live birth 
        Women with a first full term pregnancy at less than 20 
years of age have half the risk compared to nulliparous women or 
those over the age of 33. 
(3) Heredity/familial breast cancer 
             First degree relatives, presence of BRCA-1, BRCA-2  in 
families pose increased incidence risk and  likelihood of breast 
cancer.  
(4) Race  
         Risk of developing breast cancer is high in Caucasians 
compared to Asian descendants. 
(5) Breast biopsies 
        Increased risk seen in prior breast biopsies showing 
atypical hyperplasia. 
(6) Miscellaneous risk factors. 
         Estrogen exposure/ radiation exposure/carcinoma of 
contra lateral breast or endometrium/breast feeding increase 
risk of breast cancer. Geographical influence,diet,obesity, 
 exercise,environmentalcontaminants/pesticides,tobacco(periduct
al mastitis) also pose increased risk. 
            Accurate diagnosis of breast cancer is critical before 
treatment and management decisions can be made. The diagnosis 
should clearly differentiate between invasive and noninvasive breast 
tumors, and it should include a description of the histologic subtype. 
The prognosis of the patient can then be estimated based on axillary 
lymph node status, pathologic tumor size, nuclear or histologic grade, 
and rate of proliferation. ER and PR status can be used to determine 
the likelihood of response to endocrine therapy. Even if a decision is 
made not to administer adjuvant endocrine therapy, determination of 
ER and PR status at the time of diagnosis provides valuable information 
in the event that the patient subsequently has a recurrence of breast 
cancer. If trastuzumab (Herceptin) or another anti–HER-2/neu 
antibody therapy is among the potential treatment options, 
determination of HER-2/neu status is also recommended. 
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 OVERVIEW OF BREAST CANCER 
The most common clinical presentation of breast cancer is usually 
a lump in the breast identified mostly by the patient and occasionally 
by the physician. More than 66% of cases of breast cancer present as 
a lump in the breast 11% as a painful breast mass, 9% as nipple 
discharge, 5% as nipple retraction, and 4% as local edema. Other less 
common modes of presentation are ulceration of the breast, local 
erythema, arm edema, breast abscess, skin puckering.. 
   Breast cancer is most commonly located in the upper outer 
quadrant of the breast (47-50%). The upper inner quadrant is the site 
in 12 to 15% of cases, the lower inner in 2-5%, and the lower outer in 
6-12% of presentations. Centrally located lesions, beneath the nipple 
and areola presenting as Paget’s account for 15-22% of cases. An 
overall left preponderance has been repeatedly noted in various 
studies. 
The accuracy of diagnosis of breast cancer diagnosis by physical 
examination is 70% in most experienced hands. Tumors need to reach a 
size of about 1 cm to become palpable. Estimates of calculations 
 indicate that it takes approximately 5 years to reach this size from a 
single cell stage. 
Examination of both breasts and the axillae in meticulous fashion 
helps immensely in accurately to stage the tumor to help plan the 
modalities of further treatment. A search should be made for 
secondary deposits in the liver, lungs and bones. Rectal and vaginal 
examinations are also necessary to detect distant metastasis. 
Prominent veins in the region of tumor are indicative of blockade 
of venous return. Edema of the arm, edema of skin, peau d’orange 
appearance, satellite nodules are suggestive of tumor infiltration into 
sub-dermal and dermal lymphatics. Cervical sympathetic chain 
involvement is diagnosed by appearance of Horner’s syndrome 
INVESTIGATIVE MODALITIES 
Apart from meticulous clinical examination various investigations 
are utilized to ascertain the exact stage of tumor to plan treatment. 
(a) MAMMOGRAPHY 
The primary role of mammography is to screen asymptomatic 
women with the goal of detecting breast cancer at a smaller size and 
earlier stage than the woman's own surveillance or her doctor's 
 routine examination might ordinarily achieve. Mammography is also 
used to evaluate women with palpable abnormalities; however, its use in 
this setting is limited. The mammogram may reinforce the diagnosis of 
cancer and help avoid overlooking a malignancy.  
(b) ULTRASOUND   
           The routine use of ultrasound in the evaluation of palpable 
masses is controversial. From a purely scientific perspective, the use 
of ultrasound to evaluate palpable masses should be limited to those 
that have resisted aspiration but are still believed to be cysts. On 
occasion, a cyst may have a thick wall or be sufficiently mobile to defy 
clinically guided aspiration. The demonstration by ultrasound that 
these lesions are indeed cysts can avoid an excisional biopsy. 
Unfortunately, because a number of medicolegal cases have been 
decided or settled against radiologists who did not use ultrasound for 
palpable masses, many now practice defensively and examine all 
palpable masses with ultrasound. 
(c)BIOPSY 
      Fine-needle aspiration (FNA) guided by physical 
examination has been used effectively for years to evaluate patients 
 with palpable breast lumps. A review of 3,000 cases of nonpalpable 
lesions evaluated by FNA with histologic follow-up concluded that the 
results were comparable to FNA of palpable breast lumps. The 
sensitivity of FNA for palpable lesions ranged between 72% and 99% 
and for nonpalpable lesions between 82% and 100%. Multiple other 
studies have compared the accuracy of FNA for evaluating nonpalpable 
breast lesions with results from surgical biopsy. These studies have 
yielded mixed and conflicting results. The reported sensitivity has 
varied from 68% to 93% and the specificity from 88% to 100%. The 
false-negative rate for FNA of nonpalpable lesions ranges from 0 to 
32% and may be due to inaccurate lesion localization, small lesion size, 
deflection of the fine needle by firm masses, or a combination of 
these. Reported false-positive rates in nonpalpable lesions vary from 0 
to 6%.This is usually due to misinterpretation of atypical abnormalities 
found in areas of proliferative breast changes. The type of needle used 
for lesion sampling is different for FNA and for core biopsy and 
results in significantly different specimen material. Core biopsy is 
performed with a large cutting needle, usually 14 gauge, deployed into 
the breast by a rapid-fire, spring-loaded, automated biopsy 
 instrument, commonly called a biopsy gun. The sampled material 
consists of a core of tissue suitable for standard histologic analysis, 
familiar to most pathologists. Insufficient sampling is infrequent with 
core biopsy, because more tissue is removed and the tissue cores are 
easily seen during the procedure so that more tissue can be obtained if 
the sample is visibly inadequate. In contrast, FNA is performed with a 
20- to 22-gauge needle manually inserted into the breast. The fine 
needle yields cellular material suitable for cytologic evaluation. 
Accurate cytologic interpretation requires an experienced 
cytopathologist, which may not be available in all sites. The material 
extracted with FNA is smaller and prone to be insufficient for 
diagnosis. 
Breast needle biopsies of nonpalpable lesions, be they FNA or 
core biopsy, require imaging to guide needle placement. Imaging 
guidance can be performed with stereotactic mammography or 
ultrasound. Both imaging modalities are widely available. The choice of 
imaging technique used for guidance depends on the visibility of the 
lesion and does not affect the accuracy of the procedure. Generally, 
ultrasound guidance is preferred for masses visualized with ultrasound, 
 as it is faster and does not require breast compression, making it 
better tolerated by most patients. Stereotactic biopsy is used for 
mammographically detected lesions not identified with ultrasound. 
(d). SENTINEL LYMPH NODE BIOPSY 
Sentinel lymph node biopsy offers the possibility of reliably 
identifying patients with axillary node involvement with a low-morbidity 
operation, allowing axillary dissection to be limited to patients with 
nodal metastases who can benefit from the procedure. 
The concept of lymphatic mapping and sentinel lymph node biopsy 
was popularized by Morton et al. in patients with melanoma. The 
sentinel node is defined as the first lymph node that drains a cancer. 
Morton et al. demonstrated that the intradermal injection of a vital 
blue dye around the primary melanoma resulted in the identification of 
a sentinel node in the majority of patients, and the status of this node 
would predict the status of the remaining nodes in the nodal basin. 
This technique was subsequently adapted to breast tumors by Giuliano 
et al. A sentinel node was identified in 65.5% of cases and accurately 
predicted the status of the remaining axillary nodes in 95.6% of cases. 
The ability to identify the sentinel node improved as the technique was 
 refined, with a sentinel node found in 58.6% of the first 87 cases and 
78% of the last 50 cases. After these initial reports, lymphatic 
mapping with radiolabeled colloids alone, or a combination of a 
radiolabeled colloid and blue dye, was undertaken by a variety of 
groups.. Patient selection criteria and the technique of sentinel node 
identification varied widely in these studies. The injection of the 
radiolabeled colloid in the majority of studies was around the tumor 
sitebut in the report of Veronesi et al., subdermal injection was used. 
The dose of radioactivity, the interval from injection to operation, and 
the use of lymphoscintigraphy also varied. However, in spite of these 
variations in patient selection and technique of mapping, it is evident 
that with experience, a sentinel node can be identified in more than 
90% of cases and can predict the status of the remaining axillary 
nodes with 95% accuracy.25 
(e).ESTIMATION OF HORMONAL RECEPTORS 
The laboratory discovery and subsequent measurement of ER and 
PR in tumors has given the clinician useful and powerful tools to aid in 
the management of women with breast cancer. Overall, 30% to 40% of 
patients with metastatic breast cancer objectively respond to hormone 
 therapyA substantial fraction of patients also exists whose disease 
becomes stable, neither progressing nor regressing, for a clinically 
significant period of time. With first-line cytotoxic chemotherapy,the 
response rate is 50% to 60%. Although the response rate is higher 
than the objective response rate to hormone therapy, with 
chemotherapy, the toxicity is much greater, and the likelihood of a 
sustained response is low. Hormone therapy, on the other hand, is 
relatively nontoxic, and responses can sometimes last for years. Thus, 
hormone treatment offers several significant advantages to particular 
subsets of patients. It is now well established that measurement of ER 
levels, as well as PR levels, can distinguish those patients most likely to 
benefit from hormone therapy from those unlikely to respond, so the 
latter group may receive other more effective and appropriate 
management strategies, such as cytotoxic chemotherapy. 
Although a multitude of assay methods are available that differ 
in detail, at present all clinically practical methods for quantitating ER 
and PR are based on two distinct and mechanically different strategies. 
The first strategy involves the competitive binding of radiolabeled 
 steroid ligand to detect the receptor, whereas the second relies on 
the recognition of the receptor protein by specific antibodies. 
Ligand-Binding Methods26 
The prototype for ligand-binding methods, and the one that 
remains most in use, is the dextran-coated charcoal (DCC) assay. With 
this assay, radiolabeled steroid (ligand) is first added to homogenized 
breast tumor cytosol and is incubated, allowing the labeled steroid to 
bind all available receptor protein. For simultaneous determination of 
ER and PR, estradiol labeled with iodine125 and progestin labeled with 
tritium (3H) are used. DCC, which has the property of adsorbing 
unbound steroid, is added to the homogenate; the charcoal with 
adherent unbound steroid is then separated by centrifugation. Because 
the receptor-bound portion remains in the supernatant and the free 
fraction is found in the charcoal precipitate, the bound and unbound 
fractions can then be quantified and the results used to create a 
Scatchard plot. When the DCC assay is used to measure receptor 
levels, a range of 3H-tagged steroid is used to generate this multipoint 
plot. From the Scatchard plot, total concentration of receptor protein 
in the cytosol is obtained and is usually expressed as femtomoles of 
 receptor protein per milligram of total cytosol protein. Various cutoff 
values for separating ER+ from ER– samples are used in different 
laboratories; usually, the cutoff is between 3 and 20 fmol/mg.  
Variability in assay results can occur for a number of reasons. 
The tumor is usually divided into several portions, each to be used for 
different purposes. Tumor cellularity may be variable, with some 
regions being more necrotic or having a high proportion of connective 
or inflammatory tissue. Variation is also seen in the receptor content 
of the malignant epithelial component; areas of clonal proliferation may 
be found that are relatively richer or poorer in receptor protein. As 
mentioned above, treatment with ligands that bind ER or PR could 
influence the assay. 
Assays Using Monoclonal Antibodies27 
The second general strategy for detection of ER and PR uses 
antibodies specifically directed against epitopes unique to each 
receptor protein. These antibodies may be monoclonal or polyclonal. At 
least two methodologic variations on this general strategy are 
commonly performed: immunohistochemical (IHC) analysis and enzyme 
immunoassay (EIA). IHC analysis can be performed on thin sections of 
 tumor cut from formalin-fixed, paraffin-embedded or frozen biopsy 
specimens. Initially, 4- to 5-µm sections are cut and mounted on 
protein-coated glass slides. To increase detection sensitivity, the 
sections are sometimes first heated to uncover protein epitopes lost in 
the fixation process or from the passage of time. The sections are 
exposed to a primary antibody directed against ER or PR, and then a 
secondary antibody that recognizes the first is added to amplify the 
subsequent signal Attached to these secondary antibodies are 
enzymes, such as horseradish peroxidase that convert substrates like 
diaminobenzidine into colorized molecules on exposure to a developer. 
The sections are counterstained and can then be viewed to 
semiquantitate the amount of protein present For ER and PR, the 
staining produces distinct nuclear signals, and heterogeneity of 
staining of malignant epithelium is frequently seen. 
IHC analysis offers several advantages. It can be performed on 
fine-needle aspirates, core biopsies, small tumors, and cell blocks from 
body fluids, such as pleural effusions. It can be done on either frozen 
or fixed, paraffin-embedded archival tissue. It measures the total 
receptor protein resent, not just the unbound fraction, and is not 
 affected by very high levels of endogenous or exogenous steroids or 
tamoxifen treatment. It allows the direct quantification of receptor 
protein in the malignant cell fraction. Due to the reasons outlined 
above and its relative simplicity and lack of requirements for 
specialized equipment, it is rapidly becoming the predominant method 
for measuring ER and PR in clinical practice. 
(g).OTHER MODALITIES 
     1. XERORADIOGRAPHY/THERMOGRAPHY.  
                   Non specific,high incidence of false positives. 
       2. CHEST X-RAY/BONE SCAN/ SKELETAL SURVEY/ 
BONE MARROW ASPIRATION/LIVER STUDIES  
                   To detect distant metastasis.serve as adjunct to 
follow-up and palliation. 
       3.MRI/ PET SCAN  
                    Newer modalities of investigations. Costly but very 
effective in analysis of tumor characterisitics 
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 LOCALLY ADVANCED BREAST CANCER 
                   Breast cancer is the commonest malignant disease 
among women in the Western world accounting for 1/5 th (18%) of all 
cancers in women. Every year about one million women and several 
thousand men are diagnosed with breast cancer worldwide and 
approximately 60,000 die from it. It is also rapidly emerging as a very 
common cancer in the developing countries as well. In India, it is the 
second most common cancer in females with 75,000 new cases 
occurring every year as per the cancer registries in the country28  
                           Breast cancer is categorized into operable and 
advanced breast cancer for the management purpose. Advanced breast 
cancer is either locally advanced or metastatic disease. Locally 
advanced breast cancer (LABC) is characterized by varying clinical 
presentations such as presence of a large primary tumour (>5 cm), 
associated with or without skin or chest-wall involvement or with fixed 
(matted) axillary lymph nodes or with disease spread to the ipsilateral 
internal mammary or supraclavicular nodes in the absence of any 
evidence of distant metastases. These cancers are classified as stage 
IIB, IIIA, IIIB or IV breast cancer according to the American Joint 
 Committee for Cancer Staging and End Results Reporting. Locally 
advanced breast cancer is a very common clinical scenario especially in 
developing countries (30-60%) possibly due to various factors like lack 
of education and poor socio-economic status. With this wide spectrum 
of presentation, management of LABC is a challenge for the oncologist. 
Treatment of LABC has evolved from single modality treatment, 
consisting of radical mutilating surgery or higher doses of 
radiotherapy in inoperable disease to multimodality management 
consisting of surgery, radiation therapy (RT), chemotherapy with or 
without hormonal therapy,                                     
                 MODALITIES OF TREATMENT 
SURGERY 
Historically, surgery has been the oldest treatment for breast 
cancer, yet its enthusiasm has waxed and waned over a period of time. 
Different surgeries have been devised, discarded, rediscovered, 
changed and abandoned again in seemingly endless fashion as physicians 
sought to employ the science and technology of their own times. 
William Halsted at the end of nineteenth century described a surgical 
technique for removal of the entire breast and en bloc removal of all 
 axillary lymphatics, the chest wall muscles and at times a part of chest 
wall with the majority of cases being locally advanced in that era. With 
the success of Halstedian mastectomy, this surgery became a standard 
in the management of breast cancer. However the long-term results 
were poor with survival ranging from 13-20% at 5 years. The pioneering 
work by McWhirter et al.29 in the mid 20th century showed that less 
mutilating surgery produced results equal to that of radical 
mastectomy (RM). The switch from RM to less mutilating surgery came 
when it was largely recognized that treatment failure from breast 
cancer was largely due to systemic dissemination prior to surgery. A 
number of prospective randomized trials comparing RM with modified 
radical mastectomy (MRM) confirmed the evidence. The failure of 
Halstedian principle of en bloc extirpation of breast and draining lymph 
nodes to cure many patients of breast cancer, frequent identification 
of small breast cancer by mammography and success of moderate 
doses of RT in eliminating sub clinical foci of breast cancer led to the 
development of MRM. MRM is the term used to describe a variety of 
surgical procedures, but all involve complete removal of the breast and 
some of the axillary lymph nodes. Although it may not seem to differ 
 significantly, it seemed to represent a major departure from 
Halstedian mastectomy. Considering the above evidence, MRM became 
the standard of care as compared to RM (NIH consensus conference).  
RADIOTHERAPY 
    After the criteria of inoperability by Haagensen and Stout it 
was suggested that RT could be used alone in radical treatment of 
breast cancer. Radiation therapists in the early 20th century inherited 
and applied the concept of radical en bloc ablation. 
In the initial studies doses administered to the breast were limited by 
acute skin reactions from the available orthovoltage treatment units. 
Protracted fractionation with higher doses of upto 60 Gy showed 
improvement in survival in women with T3, T4 disease Higher doses of 
80-90 Gy were also attempted which led to higher complications such 
as cardiac and pulmonary complications, breast edema, arm edema, 
brachial plexus injury, shoulder stiffness, fibrosis and necrosis of 
chest wall. The survival of these patients who received radical 
radiotherapy alone was dismal. 
 
 
 RADIATION AND SURGERY 
 Irradiation, which was initially focused on inoperable cases, was 
then considered as an adjunct to radical surgery. Extensive experience 
using RT alone or in combination with surgery (pre or post Surgery) has 
been reported from large institutional series. In a large randomized 
trial, Kaae and Johnson demonstrated the effectiveness of RT in 
control of sub clinical disease. Initial experiences with radical surgery 
and postoperative radiotherapy showed that significant improvement in 
local control does occur when surgery is followed by RT but at the 
same time these trials consistently showed higher cardiac morbidity, 
the reason for which was the larger volume of heart and lung that was 
irradiated in order to encompass the internal mammary lymph nodes., 
An overview analysis by Cuzick (patients treated in four randomized 
trials) demonstrated equivalent survival for patients treated with RM 
Vs simple mastectomy (SM) + RT. But all these trials consistently 
showed that in the post RT arm the survival advantage due to RT was 
lost due to high treatment related cardiac mortality. The two biggest 
trials which showed unequivocal survival advantage with RT in stage II 
and III breast cancer were by Danish breast cancer group (DBCG) in 
 both premenopausal and post menopausal women. In DBCG 82b 1,708 
premenopausal women after MRM were randomly assigned to nine 
cycles of chemotherapy alone or 8 cycles of CMF chemotherapy and 
local RT. At a median follow up 114 months, the 10 year loco regional 
recurrence rate was 32% vs 9% and the overall survival 45% vs. 54%  
in the chemotherapy alone and combined chemotherapy and radiation 
therapy arm respectively. In the DBCG 82c study 1,375 
postmenopausal women with stage II and III breast cancer were 
randomly assigned to tamoxifen for 1 year + loco regional RT. At a 
median follow up of 123 months, the 10 year loco regional failure 
improved from 35% vs. 8% with the overall survival was 36% vs. 45% in 
the tamoxifen and tamoxifen + RT arms respectively. Another trial 
that showed the value of postmastectomy is the British Columbia trial, 
which clearly showed an improvement in overall survival and disease 
free survival in favor of RT in high risk women. The cardiac and 
pulmonary toxicity in these trials decreased to <2% as they included 
patients who were treated with improved radio therapeutic techniques 
and with the use of megavoltage units and more importantly cardiac 
safe techniques employing computerized planning and use of electron 
 beam for internal mammary chair portals. Therefore with the 
availability of level I evidence from these well conducted large studies, 
postoperative RT has now become the standard of care for stage III 
breast cancer. Although these above trials did include some patients 
with LABC, no specific randomized trial has addressed this category of 
disease. The practice of post mastectomy radiotherapy in LABC is 
based on the data from various large single institutional series. One 
such series from M.D. Anderson cancer centre addressing women with 
non-inflammatory LABC who were treated with mastectomy followed 
by external beam RT, showed loco regional control rate of 88% for 
stage IIIA disease and 74% for stage IIIB disease at a median follow 
up of 17.7 years with doses of 50Gy of external beam RT. As the role 
of RT was established, trials were done to compare RT alone with 
surgery followed by post op RT. Perez et al treated 281 patients with 
LABC reported a loco regional control of 81% at 5 years and 70% at 10 
years respectively in the patients treated with mastectomy and RT 
compared to 42% and 35% at 5 and 10 years respectively for RT alone. 
It was observed that with higher doses of RT there was significant 
improvement in the loco regional control. Thus RT has become an 
 integral component in the loco regional management of LABC with 
improvement in the loco regional control and survival. Radiation therapy 
to the chest wall and supraclavicular fossa (SCF) to a dose equivalent 
of 50 Gy has now become the standard even after a good and adequate 
surgery.30 
CHEMOTHERAPY 
                            After achieving reasonable local control with a 
combination of surgery and radiation therapy, the overall survival of 
LABC still remained dismal with distant metastasis the most common 
type of treatment failure, appearing in majority of patients within 24 
months.31 Therefore addressing the systemic component of the disease 
was considered important with an aim to achieve good survival in these 
women. Adjuvant chemotherapy has over the last 3-4 decades 
established a firm place in the management of operable and advanced 
breast cancer. Specifically for LABC management, both adjuvant 
systemic therapy and neoadjuvant chemotherapy (NACT) were 
developed simultaneously. In the last three decades, NACT especially 
has gained a major foothold in the management of LABC. The use of 
NACT in LABC dates back to 1973, when a regimen containing 
 doxorubicin caused prompt tumor shrinkage and thereby facilitated 
subsequent radiation therapy or mastectomy. The use of NACT in 
LABC was based on the rationale that these patients present with a 
relatively high burden of micro metastasis and therefore makes sense 
to initiate systemic therapy upfront at the earliest Further studies 
also showed that response to NACT could be considered as a short-
term surrogate marker for long-term outcome and therefore act as an 
in-vivo marker for tumor response to chemotherapy, especially in the 
primary tumor. There is however a debate in the application of this 
strategy. While the use of NACT certainly allows an early initiation of 
systemic treatment, inhibition of post surgical growth spurt, delivery 
of chemotherapy through intact tumor vasculature, in vivo assessment 
of response, and down staging of primary tumor and lymph node 
metastases to even facilitate less radical loco regional therapy, the 
local treatment for non responders could become delayed with risk of 
drug resistance, chemotherapy having to act on a larger tumor burden, 
inaccurate pathological staging and a possible increase in the risk of 
surgery and radiotherapy related complications. With the increasing 
usage of NACT, an interesting spin off was noted. Since a number of 
 patients achieved significant reduction in their tumor and nodal 
masses, it became apparent that breast conservation therapy (BCT) 
could be explored even in these patients, a possibility almost 
unimaginable in the conventional management paradigm. 
NEOADJUVANT CHEMOTHERAPY AND POST-OP CHEMOTHERAPY  
                          Multiple large randomized trials have proven the 
safety of NACT in LABC Most of these trials have shown a good 
objective response rate of about 60-80% without a detriment in 
survival as opposed to post-operative chemotherapy. The biggest 
randomized trial comparing pre-op versus post operative chemotherapy 
is NSABP B-18 in which 1523 patients with primary operable breast 
cancer were randomized to preoperative doxorubicin and 
cyclophosphamide (AC) therapy vs. postoperative AC therapy.32 Tumors 
with a clinical complete response (cCR) were further categorized as 
either pathologic complete response (pCR) or invasive cells (pINV). 
There was no significant difference in the disease free and overall 
survival in either group. However the frequency of BCT was greater in 
the NACT arm (67% for NACT Vs 60% post operative chemotherapy, 
Outcome was better in women whose tumors showed a pCR than in 
 those with a pINV, clinically partial response (cPR), or clinically no 
response (cNR) (relapse-free survival [RFS] rates, 85.7%, 76.9%, 
68.1%, and 63.9%, respectively), even when baseline prognostic 
variables were controlled. NACT is therefore considered as effective 
as postoperative chemotherapy and permits more breast conserving 
surgeries. In the light of the current evidence it may be concluded 
that although there is no survival benefit, there is no disadvantage. 
NACT leads to complete clinical response in 10-30% of patients and a 
partial response in 50-60%. Only a third of patients with a clinical CR 
have been found to have pathological CR. The best data in this regard 
comes from the NSABP B18, which showed that out of the 608 
patients that received NACT, breast tumor size was reduced in 80% of 
patients after NACT of which 36% had a cCR. Tumor size and clinical 
nodal status were independent predictors of cCR. Twenty-six percent 
of women with a cCR had a pCR. Clinical nodal response occurred in 89% 
of node-positive patients: 73% had a cCR and 44% of those had a pCR. 
There was a 37% increase in the incidence of pathologically negative 
nodes. Overall, 12% more lumpectomies were performed in the NACT 
group; in women with tumors 5.1 cm, there was a 17% increase in 
 lumpectomies. Thus approximately 13% of primary breast carcinoma 
cases exhibited both cCR and pCR. In addition 7% of patients 
exhibited a pCR in the absence of a cCR. A pCR occurred in 38% of 
those patients determined to have achieved a cCR. The assessment of 
clinical response in the axilla has yet not been standardized and is 
measured by different techniques. Kuerer et al. found that of 55 
patients with LABC who appeared to have had complete resolution of 
axillary disease by both physical examination and ultrasonography, 29 
patients (53%) had pathologic evidence of axillary metastasis after 
NACT. 
Despite the difficulty in accurately assessing the tumor response it 
has been shown that patients who achieve a complete clinical or 
pathological response have better outcome. Kuerer et al in their series 
of 372 patients with LABC observed pathological CR in 43 (12%) 
patients and showed better survival outcome in these patients as 
compared to those who did not have pCR When pathology specimens in 
the NSABP-B18 trial were reviewed, patients with the pCR exhibited a 
better OS and DFS compared with those with a pathologic partial 
response (presence of sparse invasive tumor [pPR]) or33 no pathologic 
response(pNR).  
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  TYPE OF CHEMOTHERAPY 
Over the years it has been proven in large randomized trials that 
anthracycline based chemotherapy are the most effective agents in 
the management of invasive breast cancers. The EBCTG meta- analysis 
involving 11 randomized trials comparing anthracycline based poly 
chemotherapy and non anthracycline based chemotherapy clearly 
showed a modest benefit in terms of recurrence rates and overall 
survival. The results can be further improved if anthracyclines can be 
combined with other non-cross resistant chemotherapy i.e. taxanes. 
Taxanes namely docetaxel and paclitaxel given as either single agents 
or as a combination are emerging to be quite effective in the 
management of breast cancer.34 Given the encouraging response rates 
to taxanes in metastatic breast cancer and the significant disease-
free and overall survival benefit shown by the addition of paclitaxel in 
stage II disease, taxanes are used extensively as non-cross-resistant 
agents with doxorubicin in stage III breast cancer. When docetaxel 
has been compared head -on with anthracycline based chemotherapy it 
seems to show a better response rate in selected patients as reported 
in a small series. The NSABP B-27 trial has shown that use of taxanes 
 with doxorubicin sequentially did show a better response rates in 
terms of superior partial and complete response both in estrogen 
receptor positive and negative patients. The final word regarding the 
routine use of taxanes and the choice of drug has not been conclusively 
resolved as yet and awaits confirmation from ongoing studies. 
Number of neo adjuvant chemotherapy cycles 
There is a lot of variation in the number of cycles of 
chemotherapy that are given in neo adjuvant setting in the literature. 
Investigators have administered either 3-4 cycles of chemotherapy 
were administered or chemotherapy was continued up to maximal 
response. This is an important issue, and may have several pitfalls. 
Current techniques of evaluating response to NACT (physical 
examination, mammography, and ultrasound) remain imprecise. The 
significance of small reduction in tumor mass may be difficult to 
evaluate because of peri tumoral edema and fibrosis. There is fear 
amongst the clinicians that tumor might actually grow during a 
protracted treatment of NACT. The biological significance of an early 
clinical response may be entirely different from that of a late 
response, a possibility suggested by complete lack of correlation 
 between response and outcome as shown by Pierce et al. As maximal 
response is always determined retrospectively this may result in delay 
in surgical planning and thus consequent reduction of chemotherapy  
Dose intensity 
The advantages of giving chemotherapy upto maximal response 
are that if the patient has achieved good clinical response in less than 
planned cycles, continuation of further chemotherapy consolidates the 
complete response by maintaining the dose intensity. However it is well 
known that the complete clinical response does not equate to complete 
abolition of all disease pathologically. Another advantage of continuing 
NACT upto maximal response is that it may be possible that a fixed 
number of cycles may not be enough to achieve the amount of response 
necessary to do BCT and if chemotherapy is continued there may be 
still further regression. Most of the retrospective studies have shown 
that post NACT tumor burden has a direct effect on loco regional 
control and survival. Even in control of the systemic micro metastasis 
giving more no. of cycles is beneficial and has an effect on the loco 
regional disease. This can be based on the Skipper's theory that the 
primary tumor and its micro metastasis may respond differently to 
 chemotherapy. Further data can be extrapolated from the studies in 
metastatic breast cancer. In patients with metastatic breast cancer 
the median number of cycles to achieve an objective response (mostly 
partial response) were three, whereas that required to achieve a 
complete response is five.35 
NEOADJUVANT HORMONAL THERAPY 
Efforts to improve response to chemotherapy include attempts 
to synchronize tumor cells with hormonal agents. Conte and associates 
used estrogenic recruitment in conjunction with cytotoxic 
chemotherapy and achieved a 15% clinical complete response rate. The 
3-year rate of progression-free survival was 54%. A subsequent 
randomized trial done by Chua et al. with FAC chemotherapy, with or 
without diethylstilbestrol, showed higher response and disease-free 
survival but no overall survival benefit for patients receiving 
estrogenic recruitment. Others also found higher objective response 
rates with hormonal manipulation, without improvements in overall 
survival rates. Pierce and associates and Lippman and colleagues36 at 
the NCI also used a strategy for hormonal synchronization with both 
estrogens and antiestrogens in their approach to locally advanced 
 disease. Despite complete clinical response rates of 50% with stage 
IIIA disease and 57% with inflammatory disease, the 5-year survival 
rates did not significantly differ from survival results in other series 
that did not use hormonal synchronization  
Adjuvant hormonal therapy 
Bartelink et al.37 did the largest randomized trial completed in 
patients with LABC with adjuvant hormonal therapy. A reanalysis of 
the same was done after 8 years. Specifically, 410 patients with LABC, 
including 48 women with inflammatory disease, were randomized to 
receive radiation therapy alone, radiation therapy with chemotherapy, 
radiation therapy with hormonal therapy, or radiation therapy with 
both chemotherapy and hormonal therapy. Patients who were 
randomized to receive chemotherapy received 12 cycles of CMF. 
Premenopausal women who were randomized to receive hormonal 
therapy received ovarian irradiation, whereas postmenopausal women 
who were randomized to receive hormonal therapy received tamoxifen. 
With a median follow-up of 8 years, both hormonal therapy and 
chemotherapy reduced the risk of loco regional failure from 
approximately 60% to 47%. Hormonal therapy significantly improved 
 survival, with a 25% reduction in the death hazards ratio. Unlike an 
interim analysis that showed a significant improvement in survival in 
the chemotherapy arm, this benefit did not remain statistically 
significant with further follow-up. In the most recent analysis, 
however, the greatest survival benefit was observed in women who 
received both hormonal therapy and chemotherapy with radiation, with 
a 35% reduction in the death hazards risk.  
LOCO-REGIONAL THERAPY FOLLOWING NACT 
Currently the sequencing of different modalities and their choice 
is a topic of major controversy. Oncologists across the globe have 
combined these modalities in various sequences and combinations. With 
more and more number of patients of LABC being treated with NACT a 
difference in the local therapy offered has been observed amongst 
various institutions. After NACT, surgery alone, radiotherapy alone or 
a combination of both has been attempted in the context of 
multidisciplinary management. Surgery has mainly been in the form of 
MRM, even though wide excision lumpectomy has been attempted. 
Multiple randomized trials and non-randomized studies have been 
conducted to address the issue of choosing the best local therapy 
 either alone or in combination. The Cancer and Leukemia Group B 
attempted to define the choice of local treatment following NACT in 
patients with inoperable disease. One hundred and thirteen patients 
(67% with stage IIIB disease) received 3 months of NACT with 
CAFVP. Eighty one percent of patients were deemed operable and 
randomized to either surgery or radiotherapy, followed by an 
additional 2 cycles of CAFVP. At a median follow up of 37 months, 
there was no significant difference in either DFS (29.2 vs. 24.4 
months) or OAS (39.3 vs. 39 months) between the two groups. 
However, the local recurrence rates were much higher in radiotherapy 
arm (55%) than surgery (42%). De Lena et al from Milan treated 132 
patients with three cycles of NACT (doxorubicin and vincristine) 
followed by surgery or radiation therapy, than an additional seven 
cycles of same chemotherapy. Although the group randomized to 
surgery following initial chemotherapy had better initial local control 
than those treated with radiation therapy alone (100% vs 60%). The 
short and the long term outcome in both the groups were essentially 
same (75%) after completion of the additional cycles of chemotherapy. 
The results of the study failed to indicate that surgery improved the 
 overall results including local control, over radiotherapy in a combined 
modality setting. Thus both these trials clearly showed that although 
initial local control is higher when NACT is followed by surgery there 
was no difference in ultimate local control and survival. Although no 
randomized data exists, indirect comparisons between trials that 
included only one form of regional therapy versus two types of regional 
treatment, have suggested that when both surgery and radiotherapy 
are employed, ultimate local control rates are higher than when only 
surgery or radiotherapy is utilized. However, only one randomized trial 
that addresses this question has been reported, and no significant 
differences between the two arms were detected. This trial included 
184 patients with LABC that received 2 cycles of NACT with CAFVM, 
which was followed by mastectomy and after which they were 
randomized to receive RT vs. no RT. This was then followed by 10 
additional cycles of chemotherapy. They found that those patients who 
received radiotherapy had a higher incidence of distant metastasis as 
compared to those not receiving RT. This was attributed to delayed 
institution of chemotherapy due to the use of radiotherapy and 
immunosuppresion caused by mediastinal irradiation. 38 
 BREAST CONSERVATION AND LABC 
 While MRM still perhaps remains the standard of care for the 
surgical management of women with LABC, less extensive surgeries 
(without compromising local control and/or survival) are being 
increasingly explored with the use of NACT. The down-staging of 
tumors seen in 60-70% of women not only makes them operable but 
also, on many occasions can be considered for BCT. Attention has 
therefore been directed towards the identification of patients with an 
excellent response to NACT who could possibly be the candidates for 
BCT. The goals of this approach are to achieve optimal loco regional 
control with acceptable cosmesis. A lot of interest has been generated 
in the last 15 yrs, to make BCT feasible in the patients suffering from 
large operable breast cancer (LOBC) and LABC. Several centres have 
reported their experience with combined modality therapy of LABC 
and BCT. However there is a great variability in the methods utilized, 
as well as the selection criteria for patients to undergo BCT. As in 
early breast cancer, presence of multicentric disease, extensive micro-
calcification, extensive skin changes, and lymphatic permeation are 
generally considered as contraindications for BCT in these scenarios as 
well.39 
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                 SUMMARY OF TREATMENT OPTIONS 
 Stage III (locally advanced) breast cancer is further classified 
into stage IIIA and stage IIIB disease. Stage IIIA disease is often 
operable when axillary lymph nodes are mobile. However, if the lymph 
nodes are fixed or if the tumor is very large, neoadjuvant 
chemotherapy is indicated to shrink the tumor before surgery.  
TREATMENT OPTIONS (STAGE IIIA):  
Standard: 
1. In operable cases, 1 of the following surgical procedures for 
initial treatment:  
Modified radical mastectomy.  
Radical mastectomy.  
2. Because of the high risk of local recurrence for this stage, 
radiation therapy should be considered as part of the overall 
treatment plan:  
Postoperative external-beam irradiation to the chest wall- A 
boost can be given if clinically indicated for positive or close margins.  
 3. Chemotherapy regimens with or without hormones are given in 
conjunction with the above surgical and radio therapeutic procedures. 
Chemotherapy can be given prior to surgery in cases where primary 
resection is not feasible or is technically difficult. Some equally 
effective combination chemotherapy regimens commonly used are:  
CMF: cyclophosphamide + methotrexate + fluorouracil  
CAF: cyclophosphamide + doxorubicin + fluorouracil  
CA: cyclophosphamide + doxorubicin  
Under clinical evaluation: 
1. Clinical trials evaluating the role of combination chemotherapy 
with or without hormonal manipulation are ongoing. Preliminary data 
indicate that neoadjuvant preoperative chemotherapy may allow breast 
conservation therapy in patients whose lesion and breast size would not 
have allowed this option  
2. High-dose chemotherapy with hematopoietic stem cell support.  
 
 
 STAGE IIIB         
(LOCALLY ADVANCED, INCLUDING INFLAMMATORY)  
The treatment of inflammatory breast cancer is similar to 
options for stage IIIB or IV breast cancer  
In stage IIIB breast cancer, initial surgery is generally limited 
to biopsy. Removal of residual tumor may be performed if a good 
response is achieved with chemotherapy with or without radiation 
therapy.  
Treatment options 
Standard:  
1. Core needle biopsy, fine-needle aspiration or incisional biopsy for 
diagnosis and receptor protein assay followed by preoperative 
chemotherapy. If the patient has a good response, local therapy with 
surgery and/or irradiation is recommended. If the response is poor, 
palliative radiation therapy may be recommended.  
2. Chemotherapy regimens with or without hormones are given in 
conjunction with the above surgical and radio therapeutic procedures. 
Chemotherapy can be given prior to surgery in cases where primary 
 resection is not feasible or is technically difficult. Commonly used 
chemotherapy regimens include:  
CMF: cyclophosphamide + methotrexate + fluorouracil.  
CAF: cyclophosphamide + doxorubicin + fluorouracil.  
CA: cyclophosphamide + doxorubicin.  
3. If combination chemotherapy is contraindicated, pretreatment 
with tamoxifen may be recommended for patients whose tumors are 
positive for estrogen- and progesterone-receptor proteins.  
Under clinical evaluation:  
1. Phase II studies evaluating newly developed chemotherapeutic 
or biologic agents may be considered for patients whose local disease 
is not controllable by standard measures.  
2. High-dose chemotherapy with hematopoietic cell support.  
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 AGE WISE DISTRIBUTION OF LABC
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FIGURE-1   AGE-WISE INCIDENCE OF LABC 
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FIGURE-2 AGE OF MENARCHE IN PATIENTS WITH 
LABC 
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         AGE                 NO. OF PATIENTS 
        TOTAL      PERCENTAGE    
           20+             04           10 
           30+               09           23 
           40+             12           31 
           50+             07           18 
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FIGURE-3 MENOPAUSAL STATUS IN LABC 
 
 
 
                                                     MENSTRUAL STATUS 
 
    MENSTRUAL STATUS     NO. OF PATIENTS      PERCENTAGE 
PRE-MENOPAUSAL         25         64 
POST-MENOPAUSAL         14           36 
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FIGURE-5 AGE AT FCB
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FIGURE-6 NODAL INVOLVEMENT
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FIGURE-7   CHEMOTHERAPY 
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         FIGURE-8     HISTOPATHOLOGICAL CORRELATION 
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FIGURE-9  RECURRENCE
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 OBSERVATION AND RESULTS  
 
                   A total of thirty-nine patients with the disease profile 
of labc were analyzed for the study. Patients belonged to various 
socioeconomic and geographical backgrounds.                    
                           The predominant age group of these patients was in 
the age group of 40-50 years (31%). The  next  common  age of 
occurrence being 30-40 years (23%) and 50-60 years (18%) 
respectively.  
                         The most common complaints of these patients 
included a sensation of lumps of varying sizes in the breast. About 30% 
of patients had complaints of skin manifestations like peau d’orange, 
skin ulceration, and retraction of the nipple was found in 5% of 
patients. 
                  The presentation of lymph nodal enlargement was clinically 
established in  67% of the total no. of patients.the site of occurrence 
of the carcinoma was found to be predominantly on the right side in  
65% of the studied group of patients. 
               The upper outer quadrant was the favoured location of 
occurrence of cancer in 54% of patients on the right and 29% on the 
left. 
 
               There was no specific correlation to the family history in any 
of the studied patients. Most patients had breast-fed their children 
from birth till the age of one year and no specific linkage could be 
made out in this regard.  
                 Early attainment of menarche could be inferred from the 
study with 82% of patients studied attaining menarche between ages 
of 16-18.  64% of women had not attained menopause at the time of 
affliction of the disease as borne out by the study. 
                FNAC study of the lesions prdominantly indicated the 
presence of infiltrating ductal carcinoma of grade 2 and this was well 
substantiated by the histopathological examination of the surgical 
specimens.   
             Chemotherapy with the three drug regimen of 
cyclophosphamide, methotrexate, 5-flourouracil was given in a  6 cycle 
regimen .alternative methods of chemotherapy included neoadjuvant 
 therapy and addition of adriamycin in place of methotrexate in women 
with good cardiovascular status. 
            Surgical options included mainly simple mastectomy with 
axillary clearance through the same incision with one instance of 
modified radical mastectomy and one case of completion mastectomy in 
a case of a  patient with post excision diagnosis of IDC. 
                      Post-operative complications included only minor 
complications like grade-I lymphedema and shoulder stiffness     
                       Hormonal therapy with tamoxifen formed the standard 
protocol and was given in the dosage of 10mg twice daily 
                    Radiotherapy was in the form of EBRT to the chest wall 
and supraclavicular fossa with standard field size and 25 fractions of 
therapy designed to deliver 50 Gy to the intended area. 
                   Recurrence rate of 12.8% was observed in the end of the 
study with three chest wall recurrences and two nodal recurrence (one 
in the supraclavicular nodal basin and one in  Rotter’s node) 
                            
 
 
 DISCUSSION 
  
 The results in this study are in correlation with published results 
of similar hospitals around the world. 
          LABC forms one of the most common modes of presentation of 
breast cancer in developing nations as borne out by the fact that it 
forms 40-60% of total cancers of the breast. 
          The age adjusted incidence of LABC is in correlation with 
accepted international data.this corresponds to  amean age of 48.4 
to50.6  is studies in WJSO40 and 41-50(33%) in studies at Columbia 
medical centre. 
            The paradigm shift is that witnessed in the profile of the 
disease occurring more in patients in the peri-menopausal/pre-
menopausal age group with 64% of patients in that group. 
           The site of occurrence of the LABC is predominantly on the 
right side 65% (donegan’s series-48%) and the upper outer quadrant is 
the commonest location 81 %( NCI database-35.7%; Donegan’s series-
40%) 
          The nodal positivity in LABC also parallels the absolute size of 
the tumor with an observed percentage of 67%as compared to 50.1-
64.5 in studies by Nemoto et al. 41and 80% in wjso studies.40 
 
          The histological correlate of IDC was in 89.7% of cases in 
comparison to 88.2% in wjso 40studies and 79% in the ACS survey. 
          The concepts of early menarche still continue to hold sway in 
patients with breast cancer with 82% of subjects studied in the age 
group of 16-18. 
          The patterned administration of multimodal therapy in the form 
of surgery (simple mastectomy/axillary clearance) followed by six 
cycles of chemotherapy with cyclophosphamide/ methotrexate/5-
flurouracil. 
           This was supplemented by hormonal therapy with tamoxifen in 
the dose of 20 mg daily and adjuvant radiation therapy. 
               No significant post-operative infections were noted in the 
course of the study with most patients undergoing primary closure of 
the skin after completion of surgical procedure. Complications were 
noted in some cases and included only minor degrees of lymphedema 
 and shoulder stiffness. No deaths were recorded in the study group as 
a result of surgery. 
 
              Routine follow-up done at fortnightly intervals with clinical 
examination of the patient for recurrence in the contra lateral 
breast(synchronous/metachronous),chest wall/scar site ,bilateral 
lymph nodal enlargement (clinical) and monthly ultrasonographic 
examination and bi-monthly radiological examination for distant 
metastasis was done. 
            As the period of the study was of the order of two years only  
definite prognostic indicators could not be assessed and needs further 
critical follow-up.               
               The loco regional recurrence was taken as an index of failure 
of multimodality therapy and the standardized results are envisioned 
as 12.8% compared to international data following multimodality 
therapy. 
 
 
 
  
s.no    Name of the study/author % of loco regional 
recurrence 
   1 Delarue et al            15 
  2 Baker et al         22.6 
 3 Leis et al          13.8 
 4 Perez et al          19( 5yrs)    
 5  Grohn et al           13 
  
 
 
 
 
 
 
 
 
 
  
CONCLUSION 
 The following conclusions are drawn from this study 
1. LABC is one of the most common presentations of carcinoma breast 
in this instituition . 
2. The epidemiological profile is of the age group of women in the 
perimenopausal age group of 40-50 
3. The site of occurrence of LABC is predominantly on the right side 
with the upper outer quadrant being the most common area. 
4.  Nodal affliction is one of the important prognosticators and 
histopathologically IDC grade 2 is the most common type. 
5. Multimodality therapy administered with meticulous follow-up 
provides acceptable rates of loco regional failure. 
6. The difficult conundrum of LABC still needs further analysis with 
respect to the efficacy of neo-adjuvant chemotherapy and  longer 
periods of study are essential to validate the same.  
 
 
 
  
 
 
 
 
 
 
 
ANNEXURES 
 
 
 
 
 
 
 
 
 ANNEXURE I 
PROFORMA 
Case No       Hospital No: 
Name :      Age:      Sex: M/F 
Address : 
COMPLAINTS 
• Swelling/lump in the breast 
• Swelling in the axilla 
• Ulcer over the breast 
• Discharge from the nipple 
• Changes in the nipple 
• Other complaints 
PAST HISTORY 
• Previous treatment history 
• H/o  Medications 
• H/o previous surgery in the breast 
PERSONAL HISTORY 
 
          
 MENSTRUAL HISTORY 
• Age of menarche 
• Regularity of periods 
• Character of periods   
• Age at menopause 
• Any other significant correlate 
MARITAL HISTORY/OBSTETRIC HISTORY 
•  Age at marriage  
• Age at first child birth /mode of delivery  
• Duration of breast feed 
• Last child birth 
• Parity 
• Any method of contraception used 
• Other correlates         
FAMILY HISTORY 
 Incidence of breast swelling  / Malignancy   yes / No 
GENERAL EXAMINATION 
• Built 
• Nutrition 
 • Weight 
• Temperature 
• Anaemia 
• Pulse rate / rhythm / Volume/ character 
SYSTEMIC EXAMINATION 
• CVS    
• Respiratory system 
• Abdomen – Liver palpable  / Non palpable 
• CNS 
LOCAL EXAMINATION 
• CHARACTERISATION OF SWELLING 
• Size 
• Location right breast / left breast / quadrant /  whole 
 gland 
• Surface   smooth / nodular / irregular 
• Consistency  soft  / cystic / firm / hard 
• Mobility   yes / no 
• Position of nipple : Normal / deviated  / 
 discharge/retracted 
 • Skin over and around the breast 
• Peau d’orange/skin fixity/deeper fixity 
• Examination of ulcer (if any) 
• Clinical examination of the axilla 
 
OTHER LYMPH NODES     YES / NO 
 - EXAMINATION OF SKELETAL SYSTEM  
Bony tenderness / swelling/ fracture    YES/NO 
 DIGITAL EXAMINATION 
CLINICAL DIAGNOSIS 
 
INVESTIGATIONS  
• FNAC 
• MAMMOGRAM 
• USG ABDOMEN/PELVIS 
• CHEST X-RAY 
• LIVER FUNCTION TESTS 
• OTHER ROUTINE INVSTIGATIONS 
• ECG in all leads 
 Date of surgery 
Surgical procedure done 
Post operative complications 
POST OP FOLLOW-UP 
• Histo pathological report 
CHEMOTHERAPY ADMINISTEREED 
           NEOADJUVANT/ADJUVANT- REGIMEN USED 
            CYCLES/COMPLICATIONS/RESPONSE 
HORMONAL THERAPY 
RADIOTHERAPY 
• Dosage 
• Field size 
• Fractionation 
• response 
FOLLOW-UP 
• clinical 
• post chemotherapy 
• post radiotherapy 
 
 RECURRENCE 
• type of recurrence 
• time of recurrence 
• characterization of recurrence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                         ANNEXURE II 
          EVOLUTION OF STAGING SYSTEMS 
PORTMANN CLASSIFICATION22 
Stage I                  Skin –not involved 
                              Tumor- localized to breast, mobile 
                              Metastasis –none 
Stage II                Skin- not involved 
                              Tumor –localized to breast, mobile 
                               Metastasis-few axillary nodes in microscopic 
evaluation, no other metastasis 
Stage III               Skin –edematous; extensive ulcerations, multiple 
secondary nodules 
                                   Tumor-diffusely infiltrating breast, fixation to 
chest wall, edema of breast 
                                   Metastasis-axillary nodes involved or fixed, no 
distant metastasis 
Stage IV                      Skin-involved or not involved 
                                    Tumor-localized or diffuse 
                                     Metastasis-evidence of distant metastasis 
 MANCHESTER CLASSIFICATION 194023 
  Stage I- 
      Tumor confined to breast, area of skin involvement present 
provided area is small in relation to size of the breast      
Stage II-  
       Tumor confined tom breast and associated axillary lymph nodes 
are present 
Stage III- 
       Tumor extends beyond the breast evidenced by; 
a. skin invasion of large area in relation to breast 
b. tumor fixation tom underlying muscle/ fascia : nodes 
mobile   
Stage IV – 
        Fixation or matting of lymph nodes 
        Fixation of tumor to chest wall 
        Deposits in supraclavicular nodes or opposite breast 
        Satellite nodules or distant metastasis. 
 
 
 COLUMBIA CLINICAL CLASSIFICATION (Haagenssen)12 
                                      Stage A 
No skin involvement or fixation of tumor to chest wall. Axillary 
nodes not palpable. 
                            Stage B  
No skin involvement or fixation of tumor to chest wall.clinically 
palpable nodes 2.5 cm or less no evidence of fixity to deeper 
structures or skin. 
                            Stage C 
Any one of five grave signs of advanced breast carcinoma   
            Limited edema of skin involving less than 1/3rd of skin over 
breast.          
   Skin ulceration. 
   Fixation of tumor to chest wall 
   Massive involvement of axillary nodes measuring >2.5 cm in 
transverse diameter. 
           Fixation of axillary lymph nodes to skin or underlying 
structures. 
 
                                        Stage D 
Advanced breast carcinoma 
          Combination of two or more signs under stage C 
          Satellite skin nodules/ extensive edema of skin/ edema of arm 
          Inflammatory breast cancer 
          Supraclavicular node/ internal mammary node involvement 
          Distant metastasis. 
 
                   TNM CLASSIFICATION24 
The American Joint Committee on Cancer (AJCC) has designated 
staging by TNM classification. 
 TNM definitions -- 
Primary tumor (T): 
  TX:  Primary tumor cannot be assessed 
  T0:  No evidence of primary tumor 
  Tis: Carcinoma in situ; intraductal carcinoma, lobular carcinoma in situ, 
or  Paget's disease of the nipple with no associated tumor. 
Note: Paget's disease associated with a tumor is classified according 
to the size of the tumor. 
T1:  Tumor 2.0 cm or less in greatest dimension 
T1mic: Microinvasion 0.1 cm or less in greatest dimension 
T1a: Tumor more than 0.1 but not more than 0.5 cm in greatest 
dimension 
     T1b: Tumor more than 0.5 cm but not more than 1.0 cm in greatest 
dimension 
    T1c: Tumor more than 1.0 cm but not more than 2.0 cm in greatest 
dimension 
  T2:  Tumor more than 2.0 cm but not more than 5.0 cm in greatest 
dimension 
  T3:  Tumor more than 5.0 cm in greatest dimension 
  T4:  Tumor of any size with direct extension to (a) chest wall or (b) 
skin, only as described below. 
 Note: Chest wall includes ribs, intercostal muscles, and serratus 
anterior muscle but not pectoral muscle. 
    T4a: Extension to chest wall 
    T4b: Edema (including peau d'orange) or ulceration of the skin of 
the breast or satellite skin nodules confined to the same breast 
    T4c: Both of the above (T4a and T4b) 
    T4d: Inflammatory carcinoma 
Regional lymph nodes (N): 
  NX: Regional lymph nodes cannot be assessed (e.g., previously 
removed) 
  N0: No regional lymph node metastasis 
  N1: Metastasis to movable ipsilateral axillary lymph node(s) 
  N2: Metastasis to ipsilateral axillary lymph node(s) fixed to each 
other or to other structures 
  N3: Metastasis to ipsilateral internal mammary lymph node(s) 
 
 
 Pathologic classification (pN): 
  pNX: Regional lymph nodes cannot be assessed (not removed for 
pathologic study or previously removed) 
  pN0: No regional lymph node metastasis 
  pN1: Metastasis to movable ipsilateral axillary lymph node(s) 
    pN1a: Only micrometastasis (none larger than 0.2 cm) 
    pN1b: Metastasis to lymph node(s), any larger than 0.2 cm 
      pN1bi:   Metastasis in 1 to 3 lymph nodes, any more than 0.2 cm and 
all less than 2.0 cm in greatest dimension 
      pN1bii:  Metastasis to 4 or more lymph nodes, any more than 0.2 
cm and all less than 2.0 cm in greatest dimension 
      pN1biii: Extension of tumor beyond the capsule of a lymph node 
metastasis less than 2.0 cm in greatest dimension 
      pN1biv:  Metastasis to a lymph node 2.0 cm or more in greatest 
dimension 
  pN2: Metastasis to ipsilateral axillary lymph node(s) fixed to each 
other or to other structures 
  pN3: Metastasis to ipsilateral internal mammary lymph node(s) 
Distant metastasis (M): 
  MX: Presence of distant metastasis cannot be assessed 
  M0: No distant metastasis  
  M1: Distant metastasis present (includes metastasis to ipsilateral 
      supraclavicular lymph nodes) 
 AJCC stage groupings  
 
 STAGE 0  
  Tis, N0, M0 
  
 
 STAGE I  
  T1,* N0, M0 
*T1 includes T1mic 
 
 STAGE IIA  
  T0, N1, M0 
  T1,* N1,** M0 
  T2, N0, M0 
*T1 includes T1mic 
**The prognosis of patients with pN1a disease is similar to that of 
patients 
with pN0 disease. 
 
 STAGE IIB  
  T2, N1, M0 
  T3, N0, M0 
 
 STAGE IIIA  
  T0, N2, M0 
  T1,* N2, M0 
  T2, N2, M0 
  T3, N1, M0 
  T3, N2, M0 
*T1 includes T1mic 
 
 STAGE IIIB  
  T4, Any N, M0 
  Any T, N3, M0 
 
 STAGE IV 
  Any T, Any N,M1 
     
 
 ANNEXURE III 
  NAME   AGE SYMPT.    SIZE L.N.STAT ASS.SIGN ASSH/O FAM MARI FCB/PARITY MENSTRUAL PROFILE
AOME/REG/AOMp
1 RANGAMMAL 53 LT.UOQ/LOQ 4X3 CEN./NF RET.NIP NIL 25 26/3 16/R/48
2 SARASWATHY 40 LT.UOQ 5X3 IHD NIL 24 25/2 14/R/
3 SANKARAMMAL 60 LT.UOQX10/12 5X4 CEN./NF ULCER 4X3 NIL 22 23/3 15/R/45
4 MUTHUMARI 50 RT.UOQX1/12 8X6 CEN./NF PDO/SKI.INF NIL 20 21/3 16/R/48
5 PACKIAJOTHI 27 RT.UOQX2/12 PECT.FIXITY FA+ NIL 25 26/1 16/R/
6 SELVARANI 27 RT.UOQ-1/12 5X3 CEN./NF NIL 32 36/2 16/R/
7 MANJU 41 RT.UOQ-2yrs 6X5 PECT.FIXITY NIL 18 19/2 16/R/
8 MICHAELAMMAL 27 RT.UIQ-3yrs 5X4 ANT./NF LAP.INF NIL 24 NIL 16/R/
9 SUBBULAKSHMI 33 RT.UOQ-6/12 5X3 NIL 24 26/1 16/R/
10 AHMED MALLIKA 30 LT.AllQ-2/12 15X10 HT NIL 20 23/2 14/R/
11 PAPPA 62 LT.UIQ-6/12 12X10 CEN./NF NIL 22 23/2 16/R/45
12 STELLA 30 RT.UOQ-1.5/12 5X2 CEN./NF/2 DM NIL 24 25/2 17/R
13 MUTHUSELVI 45 RT.UOQ-6/12 4X3 CEN./NF NIL 18 19/3 15/R/
14 POOMANI 35 LT.UOQ-2/12 4X3 CEN./NF NIL 16 18/4 15/R
15 SEENIAMMAL 46 LT.UOQ-2yrs 5X3 CEN./NF BR.ASTH NIL 22 23/4 18/R/45
16 ARUMUGHAM 53 RT.UOQ-1yr 5X3 ANT./NF NIL 18 19/2 16/R48
17 SINGARI 38 LT.UOQ-1yr 10X8 CEN./NF PDO/SKI.INF NIL 20 21/2 18/R
18 LOURDUAMMAL 40 RT.UOQ 12X8 CEN./NF NIL 22 24/2 17/R
19 FATHIMA 32 RT.UOQ 10X6 CEN./NF ANEMIA NIL 21 26/1 18/R
20 GANDHIMATHI 60 RT.UOQ 4X2 PDO/SKI.INF NIL 18 31/3 18/R/49
21 GURUVAMMAL 34 RT.UOQ 10X7 CEN./NF CYSTIC AREA+ NIL 20 21/1 17/R
22 ASHMA 45 LT.UOQ-6/12 6X5 NIL 20 22/3 17/R
23 VALLIMAYIL 50 RT.UOQ 4X2 PDO/ERY+ NIL 19 20/1 18/R
24 ARULMARI 65 RT.UOQ 5X3 NIL 19 20/6 18/R/50
25 VASANTHA 35 LT.UOQ 5X4 NIL 19 20/3 18/R
26 SELVI 25 LT.UIQ 7X6 NIL 18 23/2 17/R
27 ELISAMMAL 53 RT.UOQ 7X5 PAGET'S + NIL 19 20/5 17/R45
28 VELLATHAI 65 RT.allquad. MULT./NF NIL 19 28/1 17/R48
29 MOOKAMMAL 47 LT.UOQ 10X5 NIL 17 18/3 16/R
30 SEETHALAKSHMI 40 LT.UOQ 3X3 CENT./2RT.F NIL 17 18/4 16/R
31 MEENATCHI 50 RT.UOQ 3X4 CEN./NF SKIN.INF DM NIL 20 NIL 20/IRR/45
32 MUTHAMMAL 36 LT.UOQ 5X5 CEN./NF NIL 19 20/2 18/R
33 PATHIRAKALI 75 RT.UOQ 5X5 CEN./NF NIL 18 19/4 17/R48
34 POOMANI 41 RT.UOQ 5X4 CEN./NF NIL 21 30/2 18/R/
35 RAJALAKSHMI 40 RT.LIQ 6X4 CEN./NF DM NIL UNM 18/R  
 OBST.H/O BR.FD CONT   FNAC OTH.INV.              CHEMOTHERAPY SURGERY   HPE HOR.TPY      RT FOLLOW UP/RECURR
FCB/PARITY REGIME CYCLES/PRE/POST
26/3 Y IDC G2 CMF 0/0/6 TM/AC IDC TAMX2 CHEST/SCF-25 #
25/2 Y IDC G2 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
23/3 Y IDC G2 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
21/3 Y IDC G2 FAC 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
26/1 Y CMF Compl mas IDC TAMX2 CHEST/SCF-25 #
36/2 Y PS IDC G2 CMF 0/2/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
19/3 Y IDC G2 CMF 0/3/3 SM/AC IDC TAMX2 CHEST/SCF-25 #
NIL Y IDC G2 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
26/1 Y IDC G2 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
23/2 Y IDC G2 CMF 0/2/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
23/2 Y IDC G2 CMF 0/0/6 SM/AC.PO IDC TAMX2 CHEST/SCF-25 #
25/2 Y TAT IDC G2 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
19/3 Y IDC G2 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
18/4 Y IDC G2 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
23/4 Y IDC G2 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
19/2 Y IDC G2 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
21/2 Y IDC G2 CAF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
24/2 Y IDC G2 CMF 0/0/6  D1-D8 REGIME SM/AC IDC TAMX2 CHEST/SCF-25 # CHEST WALL/BONY-1 YEAR
26/1 Y IDC G2 FAC 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 # RT.SUPRACLAV.NODAL
31/3 Y IDC G2 FAC 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
19/1 Y IDC G2 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
20/3 Y LOBULAR mammo-lt.ca CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
22/3 Y IDC G2 CMF 2/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
20/6 Y IDC G2 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
20/3 Y IDC G2 CMF 0/0/6 SM/AC IDC/SecN TAMX2 CHEST/SCF-25 #
23/2 Y ADH CMF 0/0/6 SM/AC IDC/FCD TAMX2 CHEST/SCF-25 #
20/5 Y IDC G2 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
28/1 Y IDC G2 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
18/3 Y IDC G2 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
18/4 Y IDC G2 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
NIL IDC G2 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
Y IDC G2 CMF 0/0/6 MRM IDC TAMX2 CHEST/SCF-25 #
Y IDC G2 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
30/2 Y IDC G1 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
UNMARRIED IDC G2 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 #
24/6 Y IDC G4 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 # I YEAR-ROTTER NODE+
21/6 Y IDC G3 fibroadenoma.lt CMF 2/IRREGULAR SM/AC IDC TAMX2 CHEST/SCF-25 #
Y TAT IDC G2 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 # CHEST WALL-1 YEAR
Y IDC G3 CMF 0/0/6 SM/AC IDC TAMX2 CHEST/SCF-25 # CHEST WALL-1 YEAR  
 BIBLIOGRAPHY 
 
1.    DAVIDSON;PAGE-BLAND&COPELAND THE BREAST THIRD EDITION;2004 
2.     MOREHEAD JR;ANATOMY AND EMBRYOLOGY OF THE BREAST,CLIN OBST 
GYNAEC 25:353,1982 
3.  SPRATT JS;ANATOMY OF THE BREAST, MAJOR PROBL CLIN SURJ 5:1,1979 
4. SPRATT JS JR,DONEGAN WL,CANCER OF THE BREAST,ED 3,1979 
5. MONTAGU A:NATURAL SELECTION IN THE FORM OF BREAST IN 
FEMALE,JAMA,180:826,1962 
6. GIACOMETTI L,MONTAGNA W;THE NIPPLE AND AREOLA OF THE HUMAN 
FEMALE BREAST,ANAT REC 144;191,1962 
7. GRIFE RM:THE ANSA PECTORALIS: ANATOMY AND APPLICATIONS,2002 AACA 
8. MOOSMAN DA:ANATOMY OF THE PECTORAL NERVES AND THEIR 
PRESERVATION IN MODIFIED MASTECTOMY,AM J SURG,139:883,1980 
9. CUNNINGHAM L:THE ANATOMY OF THE ARTERIES AND VEINS OF THE 
BREAST,J SURG ONCOL,9:71,1977 
10. SAKKI S:ANGIOGRAPHY OF THE FEMALE BREAST:ANN CLIN RES,1974 
11. MILLER MR:CUTANEOUS INNERVATION OF THE HUMAN BREAST,ANAT REC 
135:153,1959 
12. HAAGENSEN CD: ANATOMY OF THE MAMMARY GLANDS,DISEASES OF THE 
BREAST,ED 3,1986 
13. CLARK GM: PROGNOSTIC FACTORS AND TREATMENT DECISIONS IN 
AXILLARY NODE NEGATIVE BREAST CANCER,N ENGL J MED 326:1756,1992 
 14. FISHER B,SLACK NH,BROSS JD: CANCER OF THE BREAST:SIZE OF 
NEOPLASM AND PROGNOSIS,CANCER 24:1071,1969 
15. FISHER ER,PROGNOSTIC AND THERAPEUTIC SIGNIFICANCE OF 
PATHOLOGICAL FEATURES OF BREAST CANCER,NCI MONOGR  29,1986 
16. WHO INTERNATIONAL HISTOLOGICAL CLASSIFICATION OF 
TUMOURS:GENEVA,1981 ,WHO 
17. HOGE AF:HISTOLOGICAL AND STAGING CLASSIFICATION OF BREAST 
CANCER,SOUTH MED J 75:1329,1982 
18. BLOOM  H,RICHARDSON W:HISTOLOGIC GRADING AND PROGNOSIS IN 
BREAST CANCER,BR J CANCER 11:359,1957 
19. FISHER ER:DETECTION AND SIGNIFICANCE OF OCCULT AXILLARY NODE 
METS IN BREAST CANCER,CANCER 42:2025,1978 
20. OSBORNE CK CURRENT USE OF STEROID HORMONE RECEPTOR ASSAYS IN 
BREAST CANCER,SCNA,58:777,1978 
21. HENDERSON IC ,NEJM,302:17,1980 
22. PORTMANN UV:CLEVE CLIN Q 10:41,1943 
23. PATTERSON R:THE TREATMENT OF MALIGNANT DISEASE BY RADIUM AND X-
RAYS,1948,EDWARD ARNOLD 
24. BREAST. IN: AMERICAN JOINT COMMITTEE ON CANCER: AJCC CANCER 
STAGING MANUAL. PHILADELPHIA, PA: LIPPINCOTT-RAVEN PUBLISHERS, 
5TH ED., 1997, PP 171-180. 
25. KJ 
 26. MCGUIRE WL, DE LA GARZA M, CHAMNESS GC. EVALUATION OF 
ESTROGEN RECEPTOR ASSAYS IN HUMAN BREAST CANCER TISSUE. CANCER 
RES 1977;37:637. 
27. KING WJ, GREENE GL. MONOCLONAL ANTIBODIES LOCALIZE OESTROGEN 
RECEPTOR IN THE NUCLEI OF TARGET CELLS. NATURE 1984;307:745. 
28. CHOPRA R. THE INDIAN SCENE JCO 2001;19:106S-111S 
29. MCWHIRTER R, THE VALUE OF SIMPLE MASTECTOMY AND RADIOTHERAPY 
IN THE TREATMENT OF CANCER OF THE BREAST. BRIT J RADIOL 
1948;21:599-610.  
30. GRAHAM MV, PEREZ CA, KUSKE RR, ET AL. LOCALLY ADVANCED 
(NONINFLAMMATORY) CARCINOMA OF THE BREAST: RESULTS AND 
COMPARISON OF VARIOUS TREATMENT MODALITIES. INT J RADIAT ONCOL 
BIOL PHYS 1991;21:311. 
31. HORTOBAGYI GN, BLUMENSCHEIN GR, ET AL. MULTIMODAL TREATMENT OF 
LOCALLY ADVANCED BREAST CANCER. CANCER 1983;51:763-8. 
32. WOLMARK N, WANG J, MAMOUNAS E, BRYANT J, FISHER B. 
PREOPERATIVE CHEMOTHERAPY IN PATIENTS WITH OPERABLE BREAST 
CANCER: NINE-YEAR RESULTS FROM NATIONAL SURGICAL ADJUVANT 
BREAST AND BOWEL PROJECT B-18. J NATL CANCER INST MONOGR 
2001;30:96-102.   
33. FISHER ER, WANG J, BRYANT J, ET AL. PATHOBIOLOGY OF PREOPERATIVE 
CHEMOTHERAPY: FINDINGS FROM THE NATIONAL SURGICAL ADJUVANT 
 BREAST AND BOWEL (NSABP) PROTOCOL B-18. CANCER 2002;95:681-
95. 
34. SMITH IC, HEYS SD, HUTCHEON AW, ET AL. NEOADJUVANT 
CHEMOTHERAPY IN BREAST CANCER: SIGNIFICANTLY ENHANCED RESPONSE 
WITH DOCETAXEL. J CLIN ONCOL 2002;20:1456-66.   
35. SCHABEL FM. CONCEPTS FOR SYSTEMIC TREATMENT OF 
MICROMETASTASES. CANCER 1975;30:15-24.   
36. LIPPMAN ME, CASSIDY J, WESLEY M, ET AL. A RANDOMIZED ATTEMPT TO 
INCREASE THE EFFICACY OF CYTOTOXIC CHEMOTHERAPY IN METASTATIC 
BREAST CANCER BY HORMONAL SYNCHRONIZATION. J CLIN ONCOL 
1984;2:28.  
37. BARTELINK H, RUBEN RD, ET AL. HORMONAL THERAPY PROLONGS 
SURVIVAL IN IRRADIATED LOCALLY ADVANCED BREAST CANCER: A 
EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER 
RANDOMIZED PHASE III TRIAL. J CLIN ONCOL 1997;15:207.   
38. PAPAIOANNOU A, LISSAIOS B, VASILAROS S, ET AL. PRE- AND 
POSTOPERATIVE CHEMOENDOCRINE TREATMENT WITH OR WITHOUT 
POSTOPERATIVE RADIOTHERAPY FOR LOCALLY ADVANCED BREAST 
CANCER. CANCER 1983;51:1284-90.  
39. SINGLETARY S, MCNEESE M, HORTOBAGYI G. FEASIBILITY OF BREAST 
CONSERVATION SURGERY AFTER INDUCTION CHEMOTHERAPY FOR LOCALLY 
ADVANCED BREAST CARCINOMA. CANCER 1991;69:2849.  
40. WJSO:  CLINICAL CONSIDERATES IN BREAST CANCER 
 41. NEMOTO T ET AL:CANCER 45:2917,1980 
42. HUTTER RVP: CANCER 46:961,1980 
43. DELARUE NC ET AL:SURGICAL GYNAEC AND OBSTETRICS 129:79,1969 
44. BAKER RR ET AL: ANN SURG,189:553,1979 
45. PEREZ CA, GRAHAM ML, ET AL. MANAGEMENT OF LOCALLY ADVANCED 
BREAST CARCINOMA OF THE BREAST. I. NON-INFLAMMATORY. CANCER 
1994;74:453-65 
46. GROHN P ET AL:ADJUVANT POSTOPERATIVE 
CHEMOTHERAPY,RADIOTHERAPY,HORMONAL THERAPYIN LOCALLY 
ADVANCED BREAST CANCER,CANCER,54:670,1984 
47. HORTOBAGYI GN, SINGLETARY SE. TREATMENT OF LOCALLY ADVANCED 
AND INFLAMMATORY BREAST CANCER. IN. DISEASE OF THE BREAST, 2ND 
ED. EDITOR. HARRIS JR. PHILADELPHIA: PUB. LIPPINCOTT, WILLIAMS AND 
WILKINS; 2000. P. 645-60.  
48. BAILEY & LOVE’S SHORT PRACTICE OF SURGERY. 24TH EDITION EDITED BY 
R.C.G.  RUSSELL, NORMAN S.WILLIAMS & CHRISTOPHER 
J.K.BULSTRODE 
 
49.    PRINCIPLES OF SURGERY 7TH EDITION SEYMOUR I. SCHWARTZ, G. TOM 
SHIRES, FRANK  C SPENCER , WENDY COWLES HASSUR 
 
50.   ESSENTIAL  SURGICAL PRACTICE. HIGHER SURGICAL TRAINING IN 
GENERAL SURGERY . FOURTH EDITION . SIR ALFRED CUSCHIERI, ROBERT 
J.C.STEELE , ABDOOL RAHIM MOOSA 
 
 51.    OXFORD TEXT BOOK OF SURGERY 1&2ND EDITIONS, EDITED BY PETER 
J.MORRIS AND RONALD A.MALT 
 
52.    SABISTON TEXT BOOK OF SURGERY SEVENTEENTH EDITION COURTNEY 
M.TOWNSEND,JR., 
53. FROM EORTC WEB SITE www.eortc.be   
54. ANONYMOUS. BREAST. IN: FLEMING ID, COOPER JS, HENSON DE, ET AL, 
EDS. AJCC CANCER STAGING MANUAL, 5TH ED. PHILADELPHIA: 
LIPPINCOTT–RAVEN1997:171. 
55. HORTOBAGYI GN, BUZDAR AU. LOCALLY ADVANCED BREAST CANCER: A 
REVIEW INCLUDING THE M.D. ANDERSON EXPERIENCE. IN: RAGAZ J, ARIEL 
IM, EDS. HIGH-RISK BREAST CANCER. BERLIN: SPRINGER-VERLAG, 
1991:382.  
56. EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP. EFFECTS OF 
ADJUVANT TAMOXIFEN AND OF CYTOTOXIC THERAPY ON MORTALITY IN 
EARLY BREAST CANCER. AN OVERVIEW OF 61 RANDOMIZED TRIALS AMONG 
28,896 WOMEN. N ENGL J MED 1988;319:1681. 
57. EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP. 
POLYCHEMOTHERAPY FOR EARLY BREAST CANCER: AN OVERVIEW OF THE 
RANDOMISED TRIALS. LANCET 1998;352:930. 
58. DELENA M, VARINI M, ZUCALI R, ET AL. MULTIMODAL TREATMENT FOR 
LOCALLY ADVANCED BREAST CANCER. RESULTS OF CHEMOTHERAPY-
RADIOTHERAPY VERSUS CHEMOTHERAPY-SURGERY. CANCER CLIN TRIALS 
1981;4:229 
 59. FISHER B, BROWN A, MAMOUNAS E, ET AL. EFFECT OF PREOPERATIVE 
CHEMOTHERAPY ON LOCAL-REGIONAL DISEASE IN WOMEN WITH OPERABLE 
BREAST CANCER: FINDINGS FROM NATIONAL SURGICAL ADJUVANT BREAST 
AND BOWEL PROJECT B-18. J CLIN ONCOL 1997;15:2483.  
60. HORTOBAGYI GN. OVERVIEW OF NEW TREATMENTS FOR BREAST CANCER. 
BREAST CANCER RES TREAT 1992;21:3.. 
.    
 
 
 
 
 
 
 
